Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;14(2):223-32.
doi: 10.2174/18715206113136660374.

Chemical metabolic inhibitors for the treatment of blood-borne cancers

Martin Villalba, Nuria Lopez-Royuela, Ewelina Krzywinska, Moeez G Rathore, Robert A Hipskind, Houda Haouas, Nerea Allende-Vega  1
Affiliations
Free PMC article
Review

Chemical metabolic inhibitors for the treatment of blood-borne cancers

Martin Villalba et al. Anticancer Agents Med Chem. 2014 Feb.
Free PMC article

Abstract

Tumor cells, including leukemic cells, remodel their bioenergetic system in favor of aerobic glycolysis. This process is called "the Warburg effect" and offers an attractive pharmacological target to preferentially eliminate malignant cells. In addition, recent results show that metabolic changes can be linked to tumor immune evasion. Mouse models demonstrate the importance of this metabolic remodeling in leukemogenesis. Some leukemias, although treatable, remain incurable and resistance to chemotherapy produces an elevated percentage of relapse in most leukemia cases. Several groups have targeted the specific metabolism of leukemia cells in preclinical and clinical studies to improve the prognosis of these patients, i.e. using L-asparaginase to treat pediatric acute lymphocytic leukemia (ALL). Additional metabolic drugs that are currently being used to treat other diseases or tumors could also be exploited for leukemia, based on preclinical studies. Finally, we discuss the potential use of several metabolic drugs in combination therapies, including immunomodulatory drugs (IMiDs) or immune cell-based therapies, to increase their efficacy and reduce side effects in the treatment of hematological cancers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial or other interests

Figures

Figure 1
Figure 1. Co-regulation of metabolism and immune function to kill tumor cells
Metabolic drugs such as DCA and Metformin induce OXPHOS that up-regulate the MHC-I expression, immunomodulators (IMiDs) and IL-2 stimulate the anti-tumor activity of effector immune cells (CTL and NK cells). This strategy will help the CTLs to recognize and bind to the MHC-I complex. In contrast, inhibition of OXPHOS reduces MHC-I expression and Natural Killer cells (NK) will recognize the absence of MHC-I and the stress signals. GLS inhibitors could induced NK activation by these means.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. - PubMed
    1. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6(11):836–848. - PubMed
    1. Cheong H, Lu C, Lindsten T, Thompson CB. Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol. 2012;30(7):671–678. - PMC - PubMed
    1. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG) Leukemia. 2009;23(6):1152–1157. - PubMed
    1. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199–213. - PubMed

Publication types

MeSH terms